The task of this Core is to provide well characterized, high-quality human-derived biospecimens required by the projects and to insure that longitudinal, structured, clinical information related to treatment and outcome is collected from the patient donors of those specimens. The primary substrate for these genetic characterization projects is a unique resource consisting of whole-organ maps that will provide histologic characterization and sufficient DNA and RNA to allow multiple experiments to be done on the same samples. This provides an unprecedented opportunity to cross-validate biologic insights coming from these different experimental platforms, and should provide, by far, the most complete view of urothelial carcinogenesis and progression ever realized. This Core will serve as a model for addressing the difficult problems of cross investigator and cross-institutional data exchange, issues of significant interest for the broader context of Texas cancer research. This Core will provide a web-based portal that will allow all investigators to browse and query the contents of the biorepository, de-identified clinical data, and translational research resources such as Standard Operating Procedures, reagent details, and primary datasets.
The specific aims for the core are as follows:
Specific Aim 1 : Provide pathologic review of all tissues.
Specific Aim 2 : Maintain a urothelial biospecimen repository, Specific Aim 3: Provide professional and technical services for the preparation and quality control of molecular analytes from the biospecimen repository.
Specific Aim 4 : Abstract clinical information for all patients providing biospecimens.
Specific Aim 5 : Capture longitudinal clinical follow-up on all patients providing biospecimens.
Specific Aim 6 : Assure that all information related to the SPORE Project is exchangeable.
Specific Aim 7 : Provide all SPORE Investigators with a common portal for access to Project data, including support for ad hoc query across projects and domains

Public Health Relevance

The projects of this SPORE will use human cancer bladder specimens and human bladder cancer cell lines for translational research directed toward improving the detection, prevention, and treatment of human bladder cancer. The Core will provide the investigators at The University of Texas MD Anderson Cancer Center as well as other collaborating institutions with high quality tissue samples from patients with bladder cancer diagnosed, treated, and followed in our institution. Standardized and centralized procedures have been established for tissue procurement, quality control, processing, storage, and distribution of samples to individual investigators. They will ensure optimal utilization of the samples according to the guidelines established by the Tissue Committee and IRB regulations.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
United States
Zip Code
Lin, Moubin; Zhang, Liren; Hildebrandt, Michelle A T et al. (2017) Common, germline genetic variations in the novel tumor suppressor BAP1 and risk of developing different types of cancer. Oncotarget 8:74936-74946
Shore, Neal D; Boorjian, Stephen A; Canter, Daniel J et al. (2017) Intravesical rAd-IFN?/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. J Clin Oncol 35:3410-3416
Wang, Gang; Huang, He; Kamat, Ashish M et al. (2017) High-grade neuroendocrine carcinoma of the urachus-report of 3 cases. Hum Pathol 67:126-133
Robertson, A Gordon; Kim, Jaegil; Al-Ahmadie, Hikmat et al. (2017) Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell 171:540-556.e25
von Rundstedt, Friedrich-Carl; Mata, Douglas A; Kryvenko, Oleksandr N et al. (2017) Utility of Clinical Risk Stratification in the Selection of Muscle-Invasive Bladder Cancer Patients for Neoadjuvant Chemotherapy: A Retrospective Cohort Study. Bladder Cancer 3:35-44
Williams, Stephen B; Kamat, Ashish M; Mmeje, Chinedu et al. (2017) Genetic variants in the inflammation pathway as predictors of recurrence and progression in non-muscle invasive bladder cancer treated with Bacillus Calmette-Guérin. Oncotarget 8:88782-88791
Mobley, Aaron; Zhang, Shizhen; Bondaruk, Jolanta et al. (2017) Aurora Kinase A is a Biomarker for Bladder Cancer Detection and Contributes to its Aggressive Behavior. Sci Rep 7:40714
Roth, Beat; Jayaratna, Isuru; Sundi, Debasish et al. (2017) Employing an orthotopic model to study the role of epithelial-mesenchymal transition in bladder cancer metastasis. Oncotarget 8:34205-34222
Metcalfe, Michael J; Ferguson, James E; Li, Roger et al. (2017) Impact of High-risk Features and Effect of Neoadjuvant Chemotherapy in Urothelial Cancer Patients with Invasion into the Lamina Propria on Transurethral Resection in the Absence of Deep Muscle Invasion. Eur Urol Focus :
Choi, Woonyoung; Ochoa, Andrea; McConkey, David J et al. (2017) Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset. Eur Urol 72:354-365

Showing the most recent 10 out of 237 publications